
Opinion|Videos|February 28, 2025
ASCO 2025: Highlights From TiNivo-2 Trial
Panelists discuss how recent updates in progression free survival data complement secondary endpoints of overall survival, overall response rates, and duration of response to provide a comprehensive picture of treatment efficacy.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5








































